Authors

• Vipul Jairath (ORCID: https://orcid.org/0000-0001-8603-898X)
• Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
• Stephen L. Jones (ORCID: https://orcid.org/0000-0002-1106-171X)
• Iris Dotan (ORCID: https://orcid.org/0000-0002-8005-7706)
• Marc Ferrante (ORCID: https://orcid.org/0000-0003-1492-0716)
• Peter Miles Irving (ORCID: https://orcid.org/0000-0003-0972-8148)
• Remo Panaccione
• Laurent Peyrin‐Biroulet (ORCID: https://orcid.org/0000-0003-2536-6618)
• Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
• Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
• Marcelo Freire (ORCID: https://orcid.org/0000-0003-4906-7698)
• Shashi Adsul (ORCID: https://orcid.org/0000-0002-0593-1088)
• Dirk Lindner (ORCID: https://orcid.org/0000-0003-2593-1322)
• Jean–Frédéric Colombel
• S Schreiber
• P. Oberai
• Brian G. Feagan

Institutions

• Western University (CA)
• Inserm (FR)
• University of Calgary (CA)
• Guy's and St Thomas' NHS Foundation Trust (GB)
• Rabin Medical Center (IL)
• Takeda (Switzerland) (CH)
• University Hospital Schleswig-Holstein (DE)
• IRCCS Ospedale San Raffaele (IT)
• Takeda (United States) (US)
• Takeda (United Kingdom) (GB)
• Amsterdam University Medical Centers (NL)
• Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
• Takeda (Japan) (JP)
• Université de Lorraine (FR)
• University of Lübeck (DE)
• Icahn School of Medicine at Mount Sinai (US)
• KU Leuven (BE)

Publication Details

Journal

Contemporary Clinical Trials Communications

Published

2025-11-25

DOI

https://doi.org/10.1016/j.conctc.2025.101574

Primary Topic

Inflammatory Bowel Disease

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Amgen
• Pfizer
• Biogen
• Celgene
• Celltrion
• Allergan